{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T15:47:30Z","timestamp":1770738450541,"version":"3.49.0"},"reference-count":28,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2001,12,20]],"date-time":"2001-12-20T00:00:00Z","timestamp":1008806400000},"content-version":"vor","delay-in-days":141,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2001,8]]},"abstract":"<jats:p><jats:bold>OBJECTIVE<\/jats:bold> Radiotherapy (RT) has been used for many years in order to complete the cure of unsuccessfully operated acromegalic patients. Several studies have shown its efficacy in normalizing GH levels, while reports about IGF\u2010I normalization are conflicting. Moreover, data regarding other markers of disease activity, such as IGFBP\u20103 and acid\u2010labile subunit (ALS), i.e. the other two components of the circulating 150\u2003kDa complex, are lacking.<\/jats:p><jats:p><jats:bold>DESIGN<\/jats:bold> Retrospective study.<\/jats:p><jats:p><jats:bold>PATIENTS AND MEASUREMENTS<\/jats:bold> Sixty\u2010seven acromegalic patients (20 males and 47 females, aged 40\u2003\u00b1\u20036\u2003years) who underwent postoperative RT (in fractionated doses for a total of 40\u201375\u2003Gy) were followed\u2010up for 11\u2003\u00b1\u20036\u2003years (range: 1\u201326\u2003years, median: 10\u2003years). Serum GH and IGF\u2010I levels off medical therapy were measured in all patients; ALS and IGFBP\u20103 were measured in 11 patients with normalization of IGF\u2010I concentrations. Computed tomography or nuclear magnetic resonance imaging periodically assessed possible development of pituitary deficiency along with imaging of the hypothalamic\u2010pituitary region.<\/jats:p><jats:p><jats:bold>RESULTS<\/jats:bold> Forty\u2010one out of 67 patients (58%) achieved GH levels &lt;\u200a2\u00b75\u2003\u00b5g\/l by 1\u201315\u2003years after RT (mean 8\u2003\u00b1\u20036) and 37\/67 patients (55%) had normal or low IGF\u2010I levels 1\u201326\u2003years after RT (mean: 12\u2003\u00b1\u20036), a normalization of both parameters being seen in 37 patients. GH\u2003&lt;\u20032\u00b75\u2003\u00b5g\/l and normal IGF\u2010I levels were achieved in 17\/26 (65%) patients followed\u2010up for at least 15\u2003years. ALS and IGFBP\u20103 concentrations paralleled IGF\u2010I levels in all patients studied. With respect to secondary pituitary insufficiency, acquired ACTH deficiency was found in 25 patients, TSH deficiency in 20, gonadotropin deficiency in 23 and GH deficiency in seven. In total, two cases of meningioma and one pineal tumour, possibly related to RT, were seen 9\u201322\u2003years after RT.<\/jats:p><jats:p><jats:bold>CONCLUSIONS<\/jats:bold> RT is an effective, although slow\u2010acting, therapeutic tool for acromegaly, with \u2018safe\u2019 GH levels and normal IGF\u2010I concentrations being achieved in 65% of patients after 15\u2003years. IGF\u2010I levels normalize more slowly than GH levels. Radiotherapy is able to normalize the concentration of all three components of the circulating 150\u2003kDa complex. Checks for loss of pituitary function and appearance of second brain tumours must be carried out life\u2010long.<\/jats:p>","DOI":"10.1046\/j.1365-2265.2001.01294.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T10:50:20Z","timestamp":1047379820000},"page":"183-189","source":"Crossref","is-referenced-by-count":54,"title":["Efficacy of radiotherapy in normalizing serum IGF\u2010I, acid\u2010labile subunit (ALS) and IGFBP\u20103 levels in acromegaly"],"prefix":"10.1111","volume":"55","author":[{"given":"Paolo","family":"Epaminonda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Porretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Cappiello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Beck\u2010Peccoz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Faglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maura","family":"Arosio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2001,12,20]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(91)90005-O"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.9.2816"},{"key":"e_1_2_6_4_1","first-page":"1096","article-title":"Diagnostic value of the acid\u2010labile subunit in acromegaly evaluation in comparison with insulin\u2010like growth factor (IGF) I and IGF\u2010binding protein\u20101, \u20102 and \u20103","volume":"86","author":"Arosio M.","year":"2001","journal-title":"Jounal of Clinical Endocrinology and Metabolism"},{"key":"e_1_2_6_5_1","first-page":"127","volume-title":"Pituitary Tumors: Epidemiology, Pathogenesis and Management","author":"Barcel\u00f2 B.","year":"1998"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.10.3187"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1995.tb01857.x"},{"key":"e_1_2_6_8_1","unstructured":"Barreca A.M. Garrone S. Cesarone A. Arosio M. Ghizzoni L. Giordano G. Minuto F.M.(1999)Reliability of the acid\u2010labile subunit (ALS) of the 150 kDa IGF complex in GH hyper and hyposecretory states.Proceedings of the 81st Meeting of the Endocrine Society p.400(abstract)."},{"key":"e_1_2_6_9_1","first-page":"293","article-title":"An audit of outcome of treatment in acromegaly","volume":"86","author":"Bates A.S.","year":"1993","journal-title":"Quarterly Journal of Medicine"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.82.12.3941"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.7.2476"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.304.6838.1343"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03347671"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8529(18)30209-3"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.81.2.443"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.2.526"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920101)69:1<271::AID-CNCR2820690145>3.0.CO;2-U"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4613-1913-9_21"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.3.927"},{"key":"e_1_2_6_20_1","first-page":"23","article-title":"Serum acid\u2010labile subunit in adult growth hormone deficiency and acromegaly (abstract)","volume":"4","author":"Hoffman D.M.","year":"1997","journal-title":"Endocrinology and Metabolism"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.21.3.0399"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1009969921497"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1990.tb00862.x"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(90)90432-J"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1009974005567"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.5.2068"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1530\/eje.0.1380160"},{"key":"e_1_2_6_28_1","first-page":"222","article-title":"Use of insulin\u2010like growth factor\u2010I (IGF\u2010I) and IGF\u2010binding protein\u20103 in the diagnosis of acromegaly and GH deficiency in adults","volume":"6","author":"Thissen J.P.","year":"1996","journal-title":"Growth Regulation"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19931001)72:7<2227::AID-CNCR2820720727>3.0.CO;2-I"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.2001.01294.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2265.2001.01294.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2265.2001.01294.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T23:49:04Z","timestamp":1695858544000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2265.2001.01294.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,8]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,8]]}},"alternative-id":["10.1046\/j.1365-2265.2001.01294.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2265.2001.01294.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,8]]}}}